+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

mRNA Vaccine Drugs Development Services Market - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 187 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6118233
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The mRNA vaccine drug development services market is undergoing rapid transformation, with expanded service offerings and advanced technologies positioning it as a key driver of global healthcare innovation. Senior decision-makers are navigating a complex ecosystem blending scientific advancement, evolving regulation, and cross-sector collaboration.

Market Snapshot: Accelerated Growth and Opportunity in mRNA Vaccine Drug Development Services

The global market for mRNA vaccine drug development services is experiencing significant momentum, fueled by heightened investment, therapeutic pipeline diversification, and growing demand for scalable production solutions. Market expansion is driven by robust adoption across therapeutic areas such as oncology, infectious diseases, and rare genetic disorders. Strategic collaborations, cutting-edge manufacturing technology, and agile regulatory consulting are reshaping market dynamics, offering varied opportunities for biopharma companies, investors, and technical leaders to optimize innovation, operational agility, and competitive positioning.

Scope & Segmentation of the mRNA Vaccine Drug Development Services Market

The report delivers comprehensive segmentation and regional analysis across core service modalities and technology platforms. Key coverage areas include:

  • Service Types: Clinical development, discovery services, manufacturing, preclinical services, and regulatory consulting.
  • Platform Types: Circular mRNA, nonreplicating mRNA, and self-amplifying mRNA with both nonviral and viral-derived platforms.
  • Delivery Technologies: Lipid nanoparticles (cationic, ionizable, neutral lipids), peptide carriers (cell penetrating, targeting peptides), and polymers (cationic polymer, dendrimers, PEG polymer).
  • Therapeutic Areas: Cardiovascular, infectious diseases (bacterial, parasitic, viral vaccines), oncology (neoantigen and personalized cancer vaccines), and rare diseases.
  • End Users: Biotechnology firms, pharmaceutical companies, full-service and specialized contract research organizations.
  • Manufacturing Scales: Commercial, laboratory, and pilot-scale production capacities.
  • Regional Coverage: Americas (including key U.S. states, Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (major economies and biotech hubs), and Asia-Pacific (China, India, Japan, Australia, and other growth markets).
  • Industry Participants: Analysis of major and emerging players, such as Lonza Group Ltd, Catalent Inc, Thermo Fisher Scientific Inc, FUJIFILM Diosynth Biotechnologies U.S.A., Inc, Samsung Biologics Co., Ltd, and others.

Key Takeaways for Senior Decision-Makers

  • Integrated service models are gaining traction as biopharma partners seek bundled solutions spanning discovery through commercial production.
  • Adoption of modular manufacturing infrastructure and single-use technologies supports rapid scale-up while reducing operational risks.
  • Digital transformation efforts, such as AI-guided process analytics and cloud-based project management, are streamlining project timelines and enhancing collaboration.
  • Emerging delivery systems, including novel lipid and polymer platforms, are expanding therapeutic potential and differentiation opportunities for service providers.
  • Regional hubs are leveraging local expertise and public-private partnerships to drive specialized research, clinical development, and onshoring of production capabilities.
  • Vendor selection is increasingly tied to the ability to adapt to evolving regulatory requirements and ensure supply chain resilience.

Tariff Impact: Navigating Cost Pressures in a Changing U.S. Trade Environment

Beginning in early 2025, newly implemented United States tariffs on critical mRNA vaccine development inputs—such as lipid components, proprietary reagents, and precision manufacturing tools—have intensified procurement and production cost pressures. These tariffs are prompting service providers to renegotiate supply agreements, consider onshoring certain manufacturing steps, and re-evaluate sourcing strategies to mitigate financial volatility. The broader effect is a reevaluation of global supply chain structures to balance elevated input costs against innovation and speed-to-market objectives.

Methodology & Data Sources

This analysis is anchored in both primary and secondary research, including direct interviews with industry executives and technical leaders, alongside a comprehensive review of scientific literature, regulatory documents, tariff schedules, and financial disclosures. Data validation was achieved through triangulation and rigorous quality assurance protocols, ensuring accuracy and actionable insights for stakeholders.

Why This Report Matters

  • Enables data-driven decision-making on service model selection, investment strategy, and partnership formation in the evolving mRNA vaccine space.
  • Equips industry leaders with timely analysis of regulatory shifts, technology trends, and supply chain risks shaping next-generation vaccine development.
  • Provides granular segmentation and strategic recommendations to optimize resource allocation and accelerate product pipelines.

Conclusion

mRNA vaccine drug development services are redefining the standards for speed, flexibility, and innovation in healthcare. In-depth market intelligence supports the ability of senior decision-makers to adapt strategies and maintain a competitive edge in a fast-evolving environment.



This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Emerging lipid nanoparticle delivery systems enhancing mRNA vaccine stability and targeted immune response
5.2. Advancements in self-amplifying mRNA constructs reducing dosage requirements and improving immunogenicity
5.3. Integration of AI-driven sequence optimization accelerating mRNA vaccine design and candidate selection
5.4. Expansion of multi-antigen mRNA platform approaches for broad-spectrum infectious disease prevention
5.5. Regulatory harmonization initiatives streamlining global clinical trial approval for mRNA therapeutics
5.6. Adoption of modular manufacturing facilities enabling rapid mRNA vaccine scale-up in pandemic scenarios
5.7. Development of thermostable mRNA formulations minimizing cold chain dependencies in resource-limited settings
5.8. Collaborative public-private partnerships funding next-generation mRNA vaccine pipeline diversification
5.9. Investment in novel adjuvanting strategies to enhance durability of mRNA vaccine-induced immune memory
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. mRNA Vaccine Drugs Development Services Market, by Service Type
8.1. Introduction
8.2. Clinical Development
8.2.1. Phase I Trials
8.2.2. Phase II Trials
8.2.3. Phase III Trials
8.3. Discovery Services
8.3.1. In Vitro Evaluation
8.3.2. Mrna Construct Design
8.3.3. Target Identification
8.4. Manufacturing Services
8.4.1. Commercial Manufacturing
8.4.2. Process Development
8.4.3. Scale Up
8.5. Preclinical Services
8.5.1. Animal Model Studies
8.5.2. Toxicology Studies
8.6. Regulatory Consulting
8.6.1. Dossier Preparation
8.6.2. Submission Support
9. mRNA Vaccine Drugs Development Services Market, by Platform Type
9.1. Introduction
9.2. Circular Mrna
9.3. Nonreplicating Mrna
9.4. Self Ampli?ying Mrna
9.4.1. Nonviral Sarna
9.4.2. Viral Derived Sarna
10. mRNA Vaccine Drugs Development Services Market, by Delivery Technology
10.1. Introduction
10.2. Lipid Nanoparticle
10.2.1. Cationic Lipid
10.2.2. Ionizable Lipid
10.2.3. Neutral Lipid
10.3. Peptide
10.3.1. Cell Penetrating Peptides
10.3.2. Targeting Peptides
10.4. Polymer
10.4.1. Cationic Polymer
10.4.2. Dendrimers
10.4.3. Peg Polymer
11. mRNA Vaccine Drugs Development Services Market, by Therapeutic Area
11.1. Introduction
11.2. Cardiovascular
11.3. Infectious Disease
11.3.1. Bacterial Vaccines
11.3.2. Parasitic Vaccines
11.3.3. Viral Vaccines
11.4. Oncology
11.4.1. Neoantigen Vaccines
11.4.2. Personalized Cancer Vaccines
11.5. Rare Disease
12. mRNA Vaccine Drugs Development Services Market, by End User
12.1. Introduction
12.2. Biotechnology Firms
12.3. Contract Research Organizations
12.3.1. Full Service CROS
12.3.2. Specialized Service CROS
12.4. Pharmaceutical Companies
13. mRNA Vaccine Drugs Development Services Market, by Manufacturing Scale
13.1. Introduction
13.2. Commercial Scale
13.3. Laboratory Scale
13.4. Pilot Scale
14. Americas mRNA Vaccine Drugs Development Services Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa mRNA Vaccine Drugs Development Services Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific mRNA Vaccine Drugs Development Services Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. Lonza Group Ltd
17.3.2. Catalent Inc
17.3.3. Thermo Fisher Scientific Inc
17.3.4. FUJIFILM Diosynth Biotechnologies U.S.A., Inc
17.3.5. Samsung Biologics Co., Ltd
17.3.6. Merck KGaA
17.3.7. Evonik Industries AG
17.3.8. Wacker Chemie AG
17.3.9. AGC Biologics Inc
17.3.10. Recipharm AB
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY SERVICE TYPE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY SERVICE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY PLATFORM TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY PLATFORM TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY DELIVERY TECHNOLOGY, 2024 VS 2030 (%)
FIGURE 10. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY DELIVERY TECHNOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2030 (%)
FIGURE 12. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY MANUFACTURING SCALE, 2024 VS 2030 (%)
FIGURE 16. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY MANUFACTURING SCALE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 27. MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET: RESEARCHAI
FIGURE 28. MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET: RESEARCHSTATISTICS
FIGURE 29. MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET: RESEARCHCONTACTS
FIGURE 30. MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY SERVICE TYPE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY CLINICAL DEVELOPMENT, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY CLINICAL DEVELOPMENT, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY PHASE I TRIALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY PHASE I TRIALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY PHASE II TRIALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY PHASE II TRIALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY PHASE III TRIALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY PHASE III TRIALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY CLINICAL DEVELOPMENT, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY CLINICAL DEVELOPMENT, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY DISCOVERY SERVICES, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY DISCOVERY SERVICES, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY IN VITRO EVALUATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY IN VITRO EVALUATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY MRNA CONSTRUCT DESIGN, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY MRNA CONSTRUCT DESIGN, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY TARGET IDENTIFICATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY TARGET IDENTIFICATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY DISCOVERY SERVICES, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY DISCOVERY SERVICES, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY MANUFACTURING SERVICES, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY MANUFACTURING SERVICES, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY COMMERCIAL MANUFACTURING, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY COMMERCIAL MANUFACTURING, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY PROCESS DEVELOPMENT, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY PROCESS DEVELOPMENT, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY SCALE UP, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY SCALE UP, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY MANUFACTURING SERVICES, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY MANUFACTURING SERVICES, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY PRECLINICAL SERVICES, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY PRECLINICAL SERVICES, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY ANIMAL MODEL STUDIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY ANIMAL MODEL STUDIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY TOXICOLOGY STUDIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY TOXICOLOGY STUDIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY PRECLINICAL SERVICES, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY PRECLINICAL SERVICES, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY REGULATORY CONSULTING, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY REGULATORY CONSULTING, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY DOSSIER PREPARATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY DOSSIER PREPARATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY SUBMISSION SUPPORT, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY SUBMISSION SUPPORT, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY REGULATORY CONSULTING, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY REGULATORY CONSULTING, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY PLATFORM TYPE, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY PLATFORM TYPE, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY CIRCULAR MRNA, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY CIRCULAR MRNA, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY NONREPLICATING MRNA, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY NONREPLICATING MRNA, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY SELF AMPLIFIYING MRNA, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY SELF AMPLIFIYING MRNA, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY NONVIRAL SARNA, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY NONVIRAL SARNA, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY VIRAL DERIVED SARNA, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY VIRAL DERIVED SARNA, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY SELF AMPLIFIYING MRNA, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY SELF AMPLIFIYING MRNA, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY DELIVERY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY DELIVERY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY LIPID NANOPARTICLE, BY REGION, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY LIPID NANOPARTICLE, BY REGION, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY CATIONIC LIPID, BY REGION, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY CATIONIC LIPID, BY REGION, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY IONIZABLE LIPID, BY REGION, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY IONIZABLE LIPID, BY REGION, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY NEUTRAL LIPID, BY REGION, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY NEUTRAL LIPID, BY REGION, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY LIPID NANOPARTICLE, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY LIPID NANOPARTICLE, 2025-2030 (USD MILLION)
TABLE 83. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY PEPTIDE, BY REGION, 2018-2024 (USD MILLION)
TABLE 84. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY PEPTIDE, BY REGION, 2025-2030 (USD MILLION)
TABLE 85. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY CELL PENETRATING PEPTIDES, BY REGION, 2018-2024 (USD MILLION)
TABLE 86. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY CELL PENETRATING PEPTIDES, BY REGION, 2025-2030 (USD MILLION)
TABLE 87. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY TARGETING PEPTIDES, BY REGION, 2018-2024 (USD MILLION)
TABLE 88. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY TARGETING PEPTIDES, BY REGION, 2025-2030 (USD MILLION)
TABLE 89. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY PEPTIDE, 2018-2024 (USD MILLION)
TABLE 90. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY PEPTIDE, 2025-2030 (USD MILLION)
TABLE 91. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY POLYMER, BY REGION, 2018-2024 (USD MILLION)
TABLE 92. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY POLYMER, BY REGION, 2025-2030 (USD MILLION)
TABLE 93. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY CATIONIC POLYMER, BY REGION, 2018-2024 (USD MILLION)
TABLE 94. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY CATIONIC POLYMER, BY REGION, 2025-2030 (USD MILLION)
TABLE 95. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY DENDRIMERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 96. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY DENDRIMERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 97. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY PEG POLYMER, BY REGION, 2018-2024 (USD MILLION)
TABLE 98. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY PEG POLYMER, BY REGION, 2025-2030 (USD MILLION)
TABLE 99. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY POLYMER, 2018-2024 (USD MILLION)
TABLE 100. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY POLYMER, 2025-2030 (USD MILLION)
TABLE 101. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 102. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 103. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2024 (USD MILLION)
TABLE 104. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2025-2030 (USD MILLION)
TABLE 105. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY INFECTIOUS DISEASE, BY REGION, 2018-2024 (USD MILLION)
TABLE 106. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY INFECTIOUS DISEASE, BY REGION, 2025-2030 (USD MILLION)
TABLE 107. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY BACTERIAL VACCINES, BY REGION, 2018-2024 (USD MILLION)
TABLE 108. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY BACTERIAL VACCINES, BY REGION, 2025-2030 (USD MILLION)
TABLE 109. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY PARASITIC VACCINES, BY REGION, 2018-2024 (USD MILLION)
TABLE 110. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY PARASITIC VACCINES, BY REGION, 2025-2030 (USD MILLION)
TABLE 111. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY VIRAL VACCINES, BY REGION, 2018-2024 (USD MILLION)
TABLE 112. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY VIRAL VACCINES, BY REGION, 2025-2030 (USD MILLION)
TABLE 113. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2024 (USD MILLION)
TABLE 114. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY INFECTIOUS DISEASE, 2025-2030 (USD MILLION)
TABLE 115. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
TABLE 116. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2030 (USD MILLION)
TABLE 117. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY NEOANTIGEN VACCINES, BY REGION, 2018-2024 (USD MILLION)
TABLE 118. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY NEOANTIGEN VACCINES, BY REGION, 2025-2030 (USD MILLION)
TABLE 119. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY PERSONALIZED CANCER VACCINES, BY REGION, 2018-2024 (USD MILLION)
TABLE 120. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY PERSONALIZED CANCER VACCINES, BY REGION, 2025-2030 (USD MILLION)
TABLE 121. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 122. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 123. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY RARE DISEASE, BY REGION, 2018-2024 (USD MILLION)
TABLE 124. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY RARE DISEASE, BY REGION, 2025-2030 (USD MILLION)
TABLE 125. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 126. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 127. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY BIOTECHNOLOGY FIRMS, BY REGION, 2018-2024 (USD MILLION)
TABLE 128. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY BIOTECHNOLOGY FIRMS, BY REGION, 2025-2030 (USD MILLION)
TABLE 129. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2024 (USD MILLION)
TABLE 130. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2025-2030 (USD MILLION)
TABLE 131. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY FULL SERVICE CROS, BY REGION, 2018-2024 (USD MILLION)
TABLE 132. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY FULL SERVICE CROS, BY REGION, 2025-2030 (USD MILLION)
TABLE 133. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY SPECIALIZED SERVICE CROS, BY REGION, 2018-2024 (USD MILLION)
TABLE 134. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY SPECIALIZED SERVICE CROS, BY REGION, 2025-2030 (USD MILLION)
TABLE 135. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2024 (USD MILLION)
TABLE 136. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2025-2030 (USD MILLION)
TABLE 137. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 138. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 139. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY MANUFACTURING SCALE, 2018-2024 (USD MILLION)
TABLE 140. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY MANUFACTURING SCALE, 2025-2030 (USD MILLION)
TABLE 141. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY COMMERCIAL SCALE, BY REGION, 2018-2024 (USD MILLION)
TABLE 142. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY COMMERCIAL SCALE, BY REGION, 2025-2030 (USD MILLION)
TABLE 143. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY LABORATORY SCALE, BY REGION, 2018-2024 (USD MILLION)
TABLE 144. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY LABORATORY SCALE, BY REGION, 2025-2030 (USD MILLION)
TABLE 145. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY PILOT SCALE, BY REGION, 2018-2024 (USD MILLION)
TABLE 146. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY PILOT SCALE, BY REGION, 2025-2030 (USD MILLION)
TABLE 147. AMERICAS MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
TABLE 148. AMERICAS MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY SERVICE TYPE, 2025-2030 (USD MILLION)
TABLE 149. AMERICAS MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY CLINICAL DEVELOPMENT, 2018-2024 (USD MILLION)
TABLE 150. AMERICAS MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY CLINICAL DEVELOPMENT, 2025-2030 (USD MILLION)
TABLE 151. AMERICAS MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY DISCOVERY SERVICES, 2018-2024 (USD MILLION)
TABLE 152. AMERICAS MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY DISCOVERY SERVICES, 2025-2030 (USD MILLION)
TABLE 153. AMERICAS MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY MANUFACTURING SERVICES, 2018-2024 (USD MILLION)
TABLE 154. AMERICAS MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY MANUFACTURING SERVICES, 2025-2030 (USD MILLION)
TABLE 155. AMERICAS MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY PRECLINICAL SERVICES, 2018-2024 (USD MILLION)
TABLE 156. AMERICAS MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY PRECLINICAL SERVICES, 2025-2030 (USD MILLION)
TABLE 157. AMERICAS MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY REGULATORY CONSULTING, 2018-2024 (USD MILLION)
TABLE 158. AMERICAS MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY REGULATORY CONSULTING, 2025-2030 (USD MILLION)
TABLE 159. AMERICAS MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY PLATFORM TYPE, 2018-2024 (USD MILLION)
TABLE 160. AMERICAS MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY PLATFORM TYPE, 2025-2030 (USD MILLION)
TABLE 161. AMERICAS MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY SELF AMPLIFIYING MRNA, 2018-2024 (USD MILLION)
TABLE 162. AMERICAS MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY SELF AMPLIFIYING MRNA, 2025-2030 (USD MILLION)
TABLE 163. AMERICAS MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY DELIVERY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 164. AMERICAS MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY DELIVERY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 165. AMERICAS MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY LIPID NANOPARTICLE, 2018-2024 (USD MILLION)
TABLE 166. AMERICAS MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY LIPID NANOPARTICLE, 2025-2030 (USD MILLION)
TABLE 167. AMERICAS MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY PEPTIDE, 2018-2024 (USD MILLION)
TABLE 168. AMERICAS MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY PEPTIDE, 2025-2030 (USD MILLION)
TABLE 169. AMERICAS MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY POLYMER, 2018-2024 (USD MILLION)
TABLE 170. AMERICAS MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY POLYMER, 2025-2030 (USD MILLION)
TABLE 171. AMERICAS MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 172. AMERICAS MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 173. AMERICAS MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2024 (USD MILLION)
TABLE 174. AMERICAS MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY INFECTIOUS DISEASE, 2025-2030 (USD MILLION)
TABLE 175. AMERICAS MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 176. AMERICAS MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 177. AMERICAS MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 178. AMERICAS MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 179. AMERICAS MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2024 (USD MILLION)
TABLE 180. AMERICAS MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2025-2030 (USD MILLION)
TABLE 181. AMERICAS MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY MANUFACTURING SCALE, 2018-2024 (USD MILLION)
TABLE 182. AMERICAS MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY MANUFACTURING SCALE, 2025-2030 (USD MILLION)
TABLE 183. AMERICAS MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 184. AMERICAS MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 185. UNITED STATES MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
TABLE 186. UNITED STATES MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY SERVICE TYPE, 2025-2030 (USD MILLION)
TABLE 187. UNITED STATES MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY CLINICAL DEVELOPMENT, 2018-2024 (USD MILLION)
TABLE 188. UNITED STATES MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY CLINICAL DEVELOPMENT, 2025-2030 (USD MILLION)
TABLE 189. UNITED STATES MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY DISCOVERY SERVICES, 2018-2024 (USD MILLION)
TABLE 190. UNITED STATES MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY DISCOVERY SERVICES, 2025-2030 (USD MILLION)
TABLE 191. UNITED STATES MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY MANUFACTURING SERVICES, 2018-2024 (USD MILLION)
TABLE 192. UNITED STATES MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY MANUFACTURING SERVICES, 2025-2030 (USD MILLION)
TABLE 193. UNITED STATES MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY PRECLINICAL SERVICES, 2018-2024 (USD MILLION)
TABLE 194. UNITED STATES MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY PRECLINICAL SERVICES, 2025-2030 (USD MILLION)
TABLE 195. UNITED STATES MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY REGULATORY CONSULTING, 2018-2024 (USD MILLION)
TABLE 196. UNITED STATES MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY REGULATORY CONSULTING, 2025-2030 (USD MILLION)
TABLE 197. UNITED STATES MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY PLATFORM TYPE, 2018-2024 (USD MILLION)
TABLE 198. UNITED STATES MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY PLATFORM TYPE, 2025-2030 (USD MILLION)
TABLE 199. UNITED STATES MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY SELF AMPLIFIYING MRNA, 2018-2024 (USD MILLION)
TABLE 200. UNITED STATES MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY SELF AMPLIFIYING MRNA, 2025-2030 (USD MILLION)
TABLE 201. UNITED STATES MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY DELIVERY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 202. UNITED STATES MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY DELIVERY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 203. UNITED STATES MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY LIPID NANOPARTICLE, 2018-2024 (USD MILLION)
TABLE 204. UNITED STATES MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY LIPID NANOPARTICLE, 2025-2030 (USD MILLION)
TABLE 205. UNITED STATES MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY PEPTIDE, 2018-2024 (USD MILLION)
TABLE 206. UNITED STATES MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY PEPTIDE, 2025-2030 (USD MILLION)
TABLE 207. UNITED STATES MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY POLYMER, 2018-2024 (USD MILLION)
TABLE 208. UNITED STATES MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY POLYMER, 2025-2030 (USD MILLION)
TABLE 209. UNITED STATES MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 210. UNITED STATES MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 211. UNITED STATES MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2024 (USD MILLION)
TABLE 212. UNITED STATES MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY INFECTIOUS DISEASE, 2025-2030 (USD MILLION)
TABLE 213. UNITED STATES MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 214. UNITED STATES MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 215. UNITED STATES MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 216. UNITED STATES MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 217. UNITED STATES MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2024 (USD MILLION)
TABLE 218. UNITED STATES MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2025-2030 (USD MILLION)
TABLE 219. UNITED STATES MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY MANUFACTURING SCALE, 2018-2024 (USD MILLION)
TABLE 220. UNITED STATES MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY MANUFACTURING SCALE, 2025-2030 (USD MILLION)
TABLE 221. UNITED STATES MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 222. UNITED STATES MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 223. CANADA MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
TABLE 224. CANADA MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY SERVICE TYPE, 2025-2030 (USD MILLION)
TABLE 225. CANADA MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY CLINICAL DEVELOPMENT, 2018-2024 (USD MILLION)
TABLE 226. CANADA MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY CLINICAL DEVELOPMENT, 2025-2030 (USD MILLION)
TABLE 227. CANADA MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY DISCOVERY SERVICES, 2018-2024 (USD MILLION)
TABLE 228. CANADA MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY DISCOVERY SERVICES, 2025-2030 (USD MILLION)
TABLE 229. CANADA MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY MANUFACTURING SERVICES, 2018-2024 (USD MILLION)
TABLE 230. CANADA MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY MANUFACTURING SERVICES, 2025-2030 (USD MILLION)
TABLE 231. CANADA MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY PRECLINICAL SERVICES, 2018-2024 (USD MILLION)
TABLE 232. CANADA MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY PRECLINICAL SERVICES, 2025-2030 (USD MILLION)
TABLE 233. CANADA MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY REGULATORY CONSULTING, 2018-2024 (USD MILLION)
TABLE 234. CANADA MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY REGULATORY CONSULTING, 2025-2030 (USD MILLION)
TABLE 235. CANADA MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY PLATFORM TYPE, 2018-2024 (USD MILLION)
TABLE 236. CANADA MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY PLATFORM TYPE, 2025-2030 (USD MILLION)
TABLE 237. CANADA MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY SELF AMPLIFIYING MRNA, 2018-2024 (USD MILLION)
TABLE 238. CANADA MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY SELF AMPLIFIYING MRNA, 2025-2030 (USD MILLION)
TABLE 239. CANADA MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY DELIVERY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 240. CANADA MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY DELIVERY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 241. CANADA MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY LIPID NANOPARTICLE, 2018-2024 (USD MILLION)
TABLE 242. CANADA MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY LIPID NANOPARTICLE, 2025-2030 (USD MILLION)
TABLE 243. CANADA MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY PEPTIDE, 2018-2024 (USD MILLION)
TABLE 244. CANADA MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY PEPTIDE, 2025-2030 (USD MILLION)
TABLE 245. CANADA MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY POLYMER, 2018-2024 (USD MILLION)
TABLE 246. CANADA MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY POLYMER, 2025-2030 (USD MILLION)
TABLE 247. CANADA MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 248. CANADA MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 249. CANADA MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2024 (USD MILLION)
TABLE 250. CANADA MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY INFECTIOUS DISEASE, 2025-2030 (USD MILLION)
TABLE 251. CANADA MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 252. CANADA MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 253. CANADA MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 254. CANADA MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 255. CANADA MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2024 (USD MILLION)
TABLE 256. CANADA MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2025-2030 (USD MILLION)
TABLE 257. CANADA MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY MANUFACTURING SCALE, 2018-2024 (USD MILLION)
TABLE 258. CANADA MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY MANUFACTURING SCALE, 2025-2030 (USD MILLION)
TABLE 259. MEXICO MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
TABLE 260. MEXICO MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY SERVICE TYPE, 2025-2030 (USD MILLION)
TABLE 261. MEXICO MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY CLINICAL DEVELOPMENT, 2018-2024 (USD MILLION)
TABLE 262. MEXICO MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY CLINICAL DEVELOPMENT, 2025-2030 (USD MILLION)
TABLE 263. MEXICO MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY DISCOVERY SERVICES, 2018-2024 (USD MILLION)
TABLE 264. MEXICO MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY DISCOVERY SERVICES, 2025-2030 (USD MILLION)
TABLE 265. MEXICO MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY MANUFACTURING SERVICES, 2018-2024 (USD MILLION)
TABLE 266. MEXICO MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY MANUFACTURING SERVICES, 2025-2030 (USD MILLION)
TABLE 267. MEXICO MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY PRECLINICAL SERVICES, 2018-2024 (USD MILLION)
TABLE 268. MEXICO MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY PRECLINICAL SERVICES, 2025-2030 (USD MILLION)
TABLE 269. MEXICO MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY REGULATORY CONSULTING, 2018-2024 (USD MILLION)
TABLE 270. MEXICO MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY REGULATORY CONSULTING, 2025-2030 (USD MILLION)
TABLE 271. MEXICO MRNA VACCINE DRUGS DEVELOPMENT SERVICES MA

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this mRNA Vaccine Drugs Development Services market report include:
  • Lonza Group Ltd
  • Catalent Inc
  • Thermo Fisher Scientific Inc
  • FUJIFILM Diosynth Biotechnologies U.S.A., Inc
  • Samsung Biologics Co., Ltd
  • Merck KGaA
  • Evonik Industries AG
  • Wacker Chemie AG
  • AGC Biologics Inc
  • Recipharm AB